Adjuvant Bestatin (Ubenimex) Treatment Following Full-Dose Local Irradiation for Bladder Carcinoma

Authors

  • H. Blomgren Radiumhemmet, Karolinska Hospital, Stockholm, Sweden, and Lundbeck A/S, Valby, Denmark
  • P.-L. Esposti Radiumhemmet, Karolinska Hospital, Stockholm, Sweden, and Lundbeck A/S, Valby, Denmark
  • I. Näslund Radiumhemmet, Karolinska Hospital, Stockholm, Sweden, and Lundbeck A/S, Valby, Denmark
  • L. Johansen Radiumhemmet, Karolinska Hospital, Stockholm, Sweden, and Lundbeck A/S, Valby, Denmark
  • O. Lemming Radiumhemmet, Karolinska Hospital, Stockholm, Sweden, and Lundbeck A/S, Valby, Denmark

DOI:

https://doi.org/10.3109/02841869009093005

Keywords:

Bladder cancer, radiotherapy, bestatin

Abstract

The clinical value of adjuvant bestatin (Ubenimex) immunotherapy has been examined in a group of patients with urinary bladder cancer. Patients with non-metastatic transitional cell carcinoma of the bladder, scheduled for full-dose local irradiation therapy (64 Gy), were randomly allocated to adjuvant oral bestatin treatment (30 mg daily for at least 1 year), starting at completion of irradiation, or no bestatin. The trial included 194 evaluable patients with a follow-up period of 1.5–9.5 years. The overall survival of the two groups of patients did not differ statistically significantly (97 patients in each). Subgrouping of the patient material gave no evidence that the clinical efficacy of bestatin is related to sex, tumor category or malignancy grade.

Downloads

Download data is not yet available.

Downloads

Published

1990-01-01

How to Cite

Blomgren, H., Esposti, P.-L., Näslund, I., Johansen, L., & Lemming, O. (1990). Adjuvant Bestatin (Ubenimex) Treatment Following Full-Dose Local Irradiation for Bladder Carcinoma. Acta Oncologica, 29(6), 809–812. https://doi.org/10.3109/02841869009093005

Issue

Vol. 29 No. 6 (1990): Acta Oncologica

Section

Articles